YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced that the ...

Psyence Biomedical Ltd. ( PBM) on Monday announced that its wholly-owned Texas subsidiary, Texas Ibogaine Research Corporation (TIRC), entered a manufacturing services agreement with Benuvia ...

Texas Ibogaine Research Corporation (“TIRC”), the wholly-owned Texas subsidiary of Psyence BioMed, enters manufacturing partnership with Benuvia Operations, LLC for the planned U.S. manufacture of ...

NEW HOPE, PA — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) has exceeded its enrollment target in a pivotal hypertension ...

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

Darren Sherman, President, COO, and Director of Orchestra BioMed Holdings, Inc. Shares sold: 15,000 shares of Common Stock ...

Orchestra BioMed Holdings Inc. company and executive profile by Barron's. View the latest OBIO company infomation and executive bios.

Surmodics has acquired the business of Alta Biomed, expanding its portfolio of hemocompatible and biocompatible surface ...

Surmodics buys Alta Biomed to expand its surface technology portfolio with PzF thin-film coatings for cardiovascular and ...

Surmodics Inc. has acquired the business of Alta Biomed, a Carlsbad, California-based medical device coating and testing services company, expanding... Read More ...

September 30, 2026, surpassing full trial enrollment targetCompany reiterates prior guidance: primary endpoint data to be submitted for late-breaking presentation consideration at a major ...

Orchestra BioMed Holdings, Inc. announced that it has surpassed full enrollment in the BACKBEAT Global Pivotal Trial (?BACKBEAT Trial?), exceeding its previously announced target of 316 randomized ...